Patient No. Baseline Week 6 Week 12 Week 24
  VL CD4+ VL CD4+ VL CD4+ VL CD4+
1 180,000 325 399 299 4,670 288 6,150 367
2 ND ND 49 524 49 738 59 990
3 1,040 440 1,510 359 49 423 152 316
4 492 788 1,630 624 49 518 695 868
5 3170 934 2,250 922 1.600 959 60,200b 503
6 399 268 MV MV 78 292 84 268
7 1,540 247 511 273 3,760 299 LTFU LTFU
8 3,370 1699 1,160 1472 49 804 2,370 653
9 399 617 546 670 MV MV 233 618
10 49 160 49 456 572 532 544 532
11 49 292 49 197 49 238 49 490
12 49 571 284 612 51 203 55 690
13 49 1056 49 1277 1,340 1193 49 1462
14 1,410 967 909 906 515 647 71 955
15 49 568 49 484 49 447 49 517
16 18,800 292 MV MV 2,640 143 LTFU LTFU
17 1,100 679 89 561 109 507 49 896
18 52 449 416 528 101 509 49 622
19 1,010 1049 673 1144 49 1102 49 1134
                 
Median 751 570 416 561 90 508 71 622
Mean 13,264 633 625 665 877 547 4171 699
aAbbreviations: LTFU, lost to follow up; MV, missed visit to clinic; ND, laboratory values not done; VL, viral load.
bThis patient stopped his antiretroviral regimen 2 weeks prior to his week 24 visit, and this lead to a marked viral rebound.
Table 2: Viral Load Change (copies/mL) and CD4+ Cell Count (Cells/mm3) in Each Patient following Switch from Amprenavir to Fosamprenavira.